Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Procainamide Hydrochloride: Beyond Cardiac Blockade to Epige

    2026-04-27

    Procainamide Hydrochloride: Beyond Cardiac Blockade to Epigenetic Modulation

    Introduction

    Procainamide Hydrochloride (CAS No. 614-39-1) has long been recognized as a cornerstone compound in cardiac electrophysiology research, primarily as a sodium channel Nav1.5 blocker. However, recent investigations have unveiled its multifaceted potential, from immunomodulation to epigenetic regulation. This article delivers a granular analysis of how Procainamide Hydrochloride (SKU B4798, APExBIO) is redefining translational and preclinical workflows, particularly when integrated into advanced assay systems or paired with chemotherapeutics. We focus on its emerging role as an inhibitor of DNA methyltransferase 1 (DNMT1) and dissect the latest evidence for its use in combination liposomal therapies—areas that prior resources have not explored in equivalent technical depth.

    Mechanistic Overview: Cardiac Sodium Channel Blockade and DNMT1 Inhibition

    Procainamide Hydrochloride exerts its principal antiarrhythmic effect by selectively inhibiting cardiac sodium channels, especially Nav1.5, with an IC50 in the 3–10 μM range (source: product_spec). This mechanism underpins its utility in suppressing ventricular premature beats and ventricular tachycardia, where rapid action potential propagation must be controlled for effective rhythm management. Its action is not limited to electrophysiological modulation; the compound also displays anti-inflammatory properties by dampening neutrophil activation and cytokine output, making it relevant for research into the interface of immunity and cardiac stress (source: product_spec).

    More recently, the inhibition of DNMT1 by Procainamide Hydrochloride has garnered significant attention. By reducing DNMT1 activity, the compound can reverse aberrant DNA methylation, leading to re-expression of tumor suppressor genes and downstream inhibition of cell proliferation and migration (source: product_spec). This dual activity positions Procainamide Hydrochloride as a unique molecular tool for bridging cardiac and oncology research, an angle not thoroughly dissected in prior overviews such as the mechanism-centric review at cachannelblockers.com. While those works outline the basic mechanisms, our focus extends into how these properties are harnessed in complex experimental designs.

    Reference Insight Extraction: Combination Liposomal Therapy Unlocks New Efficacy

    The most innovative finding from Viale et al. (2016, DOI: 10.1021/acs.chemrestox.6b00207) is the demonstration that Procainamide Hydrochloride, when co-encapsulated with cisplatin (DDP) in liposomes, significantly potentiates the antiproliferative and apoptotic activity of DDP in vitro. Notably, this synergism not only enhances efficacy against cancer cell lines (e.g., A549, A2780, DOHH2) but also mitigates DDP-induced nephrotoxicity and hepatotoxicity in vivo (source: paper). The mechanistic rationale lies in altered pharmacokinetics and the formation of a less toxic DDP/PA complex, as well as improved drug delivery via high-capacity, electrostatically stabilized liposomes.

    From a practical perspective, this approach empowers researchers to design combination therapies with lower systemic toxicity and heightened selectivity. Importantly, the study provides a blueprint for the co-delivery of hydrophilic drugs, leveraging the high loading efficiency of Procainamide Hydrochloride in liposomal compartments (mean diameter ~465 nm, polydispersity index 0.3; source: paper), which is critical for scalable, reproducible oncology workflows.

    Comparative Analysis with Alternative Methods

    Unlike earlier content such as "Procainamide Hydrochloride: Applied Workflows in Cardiac and Oncology Research" (apoptosis-kit.com), which catalogs diverse experimental setups and troubleshooting, our analysis zeroes in on the science of drug co-encapsulation and its impact on pharmacodynamics. While those guides are invaluable for stepwise assay execution, they do not dissect the quantitative and mechanistic interplay between drug loading, delivery vehicle properties, and biological outcomes. Here, we contextualize why liposomal co-formulation is not merely a logistical convenience but a strategy for fundamentally altering cellular responses to chemotherapeutics.

    Alternative sodium channel blockers or epigenetic modulators typically lack the dual-action profile found in Procainamide Hydrochloride, which streamlines research workflows by reducing the need for multiple agents and minimizing off-target effects. Furthermore, the compound’s robust solubility—≥46.4 mg/mL in water, ≥22.65 mg/mL in ethanol, and ≥13.65 mg/mL in DMSO (source: product_spec)—enables flexible integration into both aqueous and organic assay systems, unlike many structurally related molecules that suffer from poor solubility or instability.

    Advanced Applications in Cardiac Electrophysiology and Oncology

    The dual-action nature of Procainamide Hydrochloride is particularly advantageous for research at the intersection of cardiac electrophysiology and oncology. In ventricular tachycardia research, its precise inhibition of Nav1.5 channels enables high-fidelity modeling of arrhythmogenic substrates, while its DNMT1 inhibition opens avenues for exploring epigenetic drivers of cardiac remodeling and tumor progression. The suppression of neutrophil activation and cytokine release further supports its use in models where inflammation complicates disease etiology.

    Beyond its established antiarrhythmic indications, the compound's ability to restore tumor suppressor gene expression by modulating DNA methylation has prompted new experimental designs, especially in synergy with platinum-based chemotherapeutics. For example, as demonstrated in reference studies, co-delivery of Procainamide Hydrochloride with cisplatin not only enhances cytotoxic activity in cancer cell lines but also offers organ-protective effects in vivo—an outcome not commonly achieved with other sodium channel blockers (source: paper).

    Readers seeking foundational details on cell viability and proliferation assays, as well as vendor selection strategies, may refer to the high-level resource at dnase-i.com. Our article, however, delves deeper into the mechanistic and translational implications of dual-action pharmacology, enabling more informed decisions regarding co-formulation and advanced assay selection.

    Protocol Parameters

    • Nav1.5 inhibition assay | 3–10 μM IC50 | Cardiac electrophysiology | Enables precise titration of antiarrhythmic effects in voltage-clamp experiments | product_spec
    • DNMT1 inhibition assay | 10–100 μM | Epigenetic modulation workflows | Facilitates demethylation and re-expression of silenced genes in oncology models | product_spec
    • Liposomal co-encapsulation | 3.1 × 10−4 M (PA) loading | Combination cancer therapy models | Achieves high hydrophilic drug retention and electrostatic stabilization | paper
    • Solubility in DMSO | ≥13.65 mg/mL | High-throughput screening | Ensures compatibility with automated liquid handling and diverse solvent systems | product_spec
    • Storage temperature | −20°C | Stock solution and bulk storage | Preserves chemical integrity for repeatable assay performance | product_spec
    • Solution stability | Use promptly, avoid long-term storage | All experimental workflows | Minimizes degradation and assay drift | workflow_recommendation

    Why this cross-domain matters, maturity, and limitations

    The cross-domain utility of Procainamide Hydrochloride—from arrhythmia modeling to epigenetic and oncology research—reflects a mature understanding of its dual mechanistic profile. The evidence for co-encapsulation with cisplatin demonstrates not only efficacy against diverse cancer cell lines but also reduced systemic toxicity, a critical consideration in translational research. However, while these findings are robust in vitro and in murine models, clinical translation remains to be fully established. Furthermore, the lack of significant antiproliferative activity for Procainamide Hydrochloride alone in cancer cell lines underscores the necessity of combination strategies for maximum benefit (source: paper).

    Conclusion and Future Outlook

    Procainamide Hydrochloride, as supplied by APExBIO, stands at the confluence of cardiac and epigenetic research, offering a validated, dual-action platform for advanced assay development. Its unique ability to modulate both electrophysiological and methylation-dependent pathways makes it indispensable for workflows seeking both mechanistic clarity and translational impact. The compelling evidence for its role in combination liposomal therapy not only enhances efficacy in oncology models but also sets a benchmark for future co-formulation strategies. Continued innovation in delivery systems and broader validation in complex models will further illuminate its full potential.

    For a comprehensive overview of applied workflows and troubleshooting tips, researchers are encouraged to consult the practical guide at apoptosis-kit.com. Our article complements this by providing a mechanistic and translational deep-dive, enabling more strategic assay design and interpretation.

    Discover more about high-purity, research-grade Procainamide Hydrochloride for your next advanced project.